AstraZeneca’s COVID-19 Antibody Treatment Scores Approval In Europe
The European Commission has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination as COVID-19 treatment…